Two key House subcommittees will not hold hearings on the controversial 340B prescription drug discount program in the near future.
The chairs of the House Energy and Commerce Committee’s Oversight and Investigations Subcommittee and its Health Committee have both suggested that House Democrats understand the importance and value of the 340B program and see other health care issues as greater priorities.
This marks a serious departure from the last session of Congress, which saw a number of hearings on the 340B program and doubts cast about the program’s objectives and future.
Learn more from the Lexology article “340B Program Gets Relief from Congressional Scrutiny.”